Arecor Ltd has successfully protected one of its key European patents.
The proceedings at the European Patent Office were in relation to a key patent of the Company’s broad portfolio that leads to the prevention of aggregation of therapeutic proteins during storage.
Arecor’s proprietary formulation technology, Arestat™, enables unparalleled biopharmaceutical product profiles across a broad range of therapies, including products that can be used outside the cold chain or highly concentrated compositions allowing convenient delivery to the patient.
They partner with leading pharmaceutical and biotech companies to deliver differentiated reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
In addition, Arecor is leveraging its technology to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides.
The Company has invested considerably into building a strong patent portfolio to protect the technology as well as the product assets that the technology enables.
Their intellectual property portfolio currently comprises 28 patent families within which 26 individual patents have been granted in key territories.
European patents can be opposed by other companies within a certain period of time following their formal grant.
The successfully defended patent protects novel compositions that are highly effective in preventing the process of aggregation of therapeutic proteins.
Aggregation is one of the main problems affecting the stability of high-value therapeutic protein products.
Those aggregated proteins used in oncology, autoimmune diseases or metabolic disorders may trigger an immune response that can negatively impact the therapeutic efficacy, as well as in some cases, the safety of administering the product.
For that reason, the levels of aggregated protein must be maintained to a minimum. The novel compositions protected by this patent can achieve exactly that and thus allow development of safe dosage forms.